Abstract
Treatment of osteoporosis remains a therapeutic challenge. The effect of Apium Nodiflorum extract on development of experimental osteoporosis, pain thresholds and carrageenan-induced inflammation has been studied in ovariectomized osteoporotic Wistar rats. After osteoporosis verification rats were randomized and received vehicle only, HPLC-standardized Apium extract (equal to 2.4 mg/kg Quercetin) or Genistein (2.5 mg/kg) for 8 weeks. To verify the effect of Apium on the development of osteoporosis, bone mineral density (BMD) and bone mineral content (BMC), bone histology and plasma levels of IL-6 and RANKL were measured 6 months after ovariectomy and 8 weeks after treatment with Apium extract or Genistein as comparator. Inflammatory hyperalgesia was induced by intraplantar injection of 1% Carrageenan. Apium extract and Genistein impeded the development of osteoporosis (significant differences were shown for BMC and BMD levels in drug vs. vehicle treated rats) and improved bone histology and histological score. Apium and Genistein decreased IL-6 level. Both treatments alleviated mechanical hyperalgesia, decreased exudative reaction and lowered inflammatory pain threshold. The results suggested that Apium extract could be an alternative therapy for post-menopausal osteoporosis.
Keywords: Apium, genistein, inflammatory hyperalgesia, osteoporosis, pain thresholds.
Current Pharmaceutical Biotechnology
Title:The Effect of Apium Nodiflorum in Experimental Osteoporosis
Volume: 16 Issue: 5
Author(s): Ana P. Tsakova, Slavina K. Surcheva, Vasya S. Bankova, Milena P. Popova, Dimitar R. Peev, Plamen R. Popivanov, Kiril L. Surchev, Mariya D. Ratkova, Lachezar K. Surchev and Mila V. Vlaskovska
Affiliation:
Keywords: Apium, genistein, inflammatory hyperalgesia, osteoporosis, pain thresholds.
Abstract: Treatment of osteoporosis remains a therapeutic challenge. The effect of Apium Nodiflorum extract on development of experimental osteoporosis, pain thresholds and carrageenan-induced inflammation has been studied in ovariectomized osteoporotic Wistar rats. After osteoporosis verification rats were randomized and received vehicle only, HPLC-standardized Apium extract (equal to 2.4 mg/kg Quercetin) or Genistein (2.5 mg/kg) for 8 weeks. To verify the effect of Apium on the development of osteoporosis, bone mineral density (BMD) and bone mineral content (BMC), bone histology and plasma levels of IL-6 and RANKL were measured 6 months after ovariectomy and 8 weeks after treatment with Apium extract or Genistein as comparator. Inflammatory hyperalgesia was induced by intraplantar injection of 1% Carrageenan. Apium extract and Genistein impeded the development of osteoporosis (significant differences were shown for BMC and BMD levels in drug vs. vehicle treated rats) and improved bone histology and histological score. Apium and Genistein decreased IL-6 level. Both treatments alleviated mechanical hyperalgesia, decreased exudative reaction and lowered inflammatory pain threshold. The results suggested that Apium extract could be an alternative therapy for post-menopausal osteoporosis.
Export Options
About this article
Cite this article as:
Tsakova P. Ana, Surcheva K. Slavina, Bankova S. Vasya, Popova P. Milena, Peev R. Dimitar, Popivanov R. Plamen, Surchev L. Kiril, Ratkova D. Mariya, Surchev K. Lachezar and Vlaskovska V. Mila, The Effect of Apium Nodiflorum in Experimental Osteoporosis, Current Pharmaceutical Biotechnology 2015; 16 (5) . https://dx.doi.org/10.2174/1389201015666141229104102
DOI https://dx.doi.org/10.2174/1389201015666141229104102 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Endothelial Dysfunction: Methods of Assessment & Implications for Cardiovascular Diseases
Current Pharmaceutical Design Therapeutic Modulation of Growth Factors and Cytokines in Regenerative Medicine
Current Pharmaceutical Design Regulatable Gene Expression Systems for Gene Therapy
Current Gene Therapy B7-H3 Immune Checkpoint Protein in Human Cancer
Current Medicinal Chemistry The Expression of Relaxin-3 in Adipose Tissue and its Effects on Adipogenesis
Protein & Peptide Letters Mechanisms of Platelet Activation in Acute Coronary Syndromes
Current Vascular Pharmacology Class- and Molecule-specific Differential Effects of Angiotensin II Type 1 Receptor Blockers
Current Pharmaceutical Design Cerebrovascular Amyloidosis and Dementia
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents New Pharmacological Approaches Using Polyphenols on the Physiopathology of Neuropathic Pain
Current Drug Targets Meet Our Editorial Board Member
Medicinal Chemistry Relevance of Aβ 1-42 Intrahippocampal Injection as An Animal Model of Inflamed Alzheimers Disease Brain
Current Alzheimer Research Vitamin D - Pivotal Nutraceutical in the Regulation of Cancer Metastasis and Angiogenesis
Current Medicinal Chemistry Rabbit Models of Ocular Diseases: New Relevance for Classical Approaches
CNS & Neurological Disorders - Drug Targets COVID-19 Invades Several Important Organs other than the Lungs: Organs Crosstalk
Coronaviruses Brain-Delivery of Zinc-Ions as Potential Treatment for Neurological Diseases: Mini Review
Drug Delivery Letters Clinical Experience with Specific COX-2 Inhibitors in Arthritis
Current Pharmaceutical Design IL-17 and its Receptor Complex as Therapeutic Targets in Arthritis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Recent Patents on Topical Application of Honey in Wound and Burn Management
Recent Patents on Inflammation & Allergy Drug Discovery Comparative Analysis of Stage Specific Gene Regulation of Apicomplexan Parasites: Plasmodium falciparum and Toxoplasma gondii
Infectious Disorders - Drug Targets Molecular Targets of FTY720 (Fingolimod)
Current Molecular Medicine